poisar

Stock

Zai Lab Limited ZLAB

$18.27+0.33%

Overview

ZLAB market data

Price History

ZLAB price chart

Valuation & Profitability

Twelve Data
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$0.16
Diluted earnings per share over the trailing twelve months.
Beta
0.76
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$12.31 – $32.35
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $16.1K · P/B 2.75 · P/S 4.53.

Company News

5 captured
Zai Lab Announces EMA Grants Orphan Drug Designation To Zocilurtatug Pelitecan, Delta-Like Ligand 3-Targeting Antibody-Drug Conjugate, For Treatment Of Pulmonary Neuroendocrine CarcinomasBenzinga · Jun 16, 2026, 11:20 AM
8-K filing — Zai Lab Ltd (ZLAB)SEC EDGAR · May 21, 2026, 9:18 PM
UnitedHealth, Regeneron Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market SessionBenzinga · May 18, 2026, 12:05 PM
Zai Lab shares are trading higher after the company announced that the FDA granted it Fast Track Designation to zocilurtatug pelitecan for the treatment of extrapulmonary neuroendocrine carcinomas following progression after standard first-line therapy.Benzinga · May 11, 2026, 2:27 PM
The FDA Grants Fast Track Designation To Zai Lab's Zocilurtatug Pelitecan (Zoci, formerly ZL-1310) for Extrapulmonary Neuroendocrine Carcinomas Following Progression After Standard First-Line TherapyBenzinga · May 11, 2026, 11:09 AM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock